Linda Marie Bavisotto MD

Hematology•Seattle, WA

Linda M. Bavisotto MD FACP, clinical research Seattle, WA

Join to View Full Profile

1532 NE 96th StreetSeattle, WA 98101
Phone+1 206-356-1714

Education & Training

St Elizabeth's Medical CenterResidency, Internal Medicine, 1981 - 1984
University of Wisconsin School of Medicine & Public HealthClass of 1981

Certifications & Licensure

WA State Medical License 1986 - 2019
WI State Medical License 1982 - 2019
American Board of Internal Medicine Internal Medicine

Clinical Trials

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
ACTIVE_NOT_RECRUITING
PHASE1
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions Start of enrollment: 2007 Aug 01
Completed
Not Applicable
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions Start of enrollment: 2007 Sep 01
Completed
Not Applicable
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer Start of enrollment: 2011 Mar 01
Unknown status
Phase 1
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia Start of enrollment: 2013 Dec 01
Completed
Phase 1
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
COMPLETED
PHASE1, PHASE2
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2015 May 01
Completed
Phase 2
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer Start of enrollment: 2015 May 01
Completed
Phase 2
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2015 May 01
Completed
Phase 2
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Start of enrollment: 2017 Feb 02
ACTIVE_NOT_RECRUITING
PHASE3
A Study Evaluating MM-310 in Patients With Solid Tumors Start of enrollment: 2017 Feb 22
Unknown status
Phase 1
Join now to see all

Publications & Presentations

PubMed

35 citations
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Antonio Omuro, Kathryn Beal, Katharine McNeill, Robert J. Young, Alissa A. Thomas
Journal of Clinical Oncology. 2018-04-23
44 citations
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.
Tibor Kovacsovics, Alice S. Mims, Mohamed E. Salama, Jeremy Pantin, Narayanam V. Rao
Blood Advances. 2018-02-27
21 citations
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy part...
Linda M. Bavisotto, David J. Ellis, Peter G. Milner, Daniel Combs, Ian Irwin
Journal of Clinical Pharmacology. 2011-04-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American College of Physicians - ACP
Fellow